Preview Mode Links will not work in preview mode

Investor Connect Podcast


Investor Connect is for investors interested in learning more about investing in startup and growth stage companies. Experienced investors share their experiences and advice with those who are considering an investment into startups and growth companies. It includes a podcast series of interviews with investors to inform others about the process of funding startups as well as a resource list and a discussion board.  

Topics include sourcing, analyzing, and researching companies. Other topics include valuations, terms Sheets, board of directors, board of advisors, due diligence, syndicates, venture capital, angels, angel networks, family offices, crowdfunding, exits, and more.

Investor Connect is a community program. We welcome your suggestions for speakers and topics which you can send to us through the Contact page. No registration is required to use the resources.  Discussion boards are available to post and answer questions about startups and growth company investing through which registration is required.

Investor Connect is a program under the Texas Open Angel Network which is a 501(c3) non-profit dedicated to the education around startup funding.

Disclaimer: Hall T. Martin is the Director of Investor Connect which is dedicated to the education of investors for early stage funding. All opinions expressed by Hall and podcast guests are solely their own opinions and do not reflect the opinion of Investor Connect. This podcast is for informational purposes only and should not be relied upon as a basis for investment decisions.

Nov 24, 2020

In this episode, Hall welcomes David Bach, MD, CEO and Founder of Optios.

Optios is a leader in the rapidly-emerging neuro-­performance industry. Based on more than a decade of work at DARPA, hundreds-of-millions of dollars of proprietary research, and close partnerships with the world's most elite organizations, Optios' guiding mission is to build an intellectual framework and platform that supports the next phase in human development. Neuroscience is the next frontier in management. Optimizing leaders' brains will soon be a critical source of competitive advantage in the business world.

Today, due to recent neuroscience advances, they (Optios) can rewire the human brain in targeted ways that profoundly enhance human performance, cognition, creative capacity, learning speed, health, and even longevity.

David Bach, MD is a Harvard-trained scientist and Founder and CEO of Optios. Prior to founding Optios, David was a serial entrepreneur, venture capitalist, management consultant, scientist, physician, martial artist, and professional cellist. As an entrepreneur, he founded and built three prior companies: Touchstone Health, Empyrean Benefit Solutions, and Leprechaun HCC Management. Each of these became a $200M+ enterprise. His venture capital experience was with TA Associates in Boston. 

After spending a decade maximizing his physical and mental performance, David created Optios to bring scientific rigor to, and create commercial applications in, the rapidly-expanding arena of applied neuroscience.

David attended Harvard College and Harvard Medical School. His scientific training was at The Dana-Farber Cancer Institute.

In this interview, David shares with Hall what led him to start working in the neuro-performance space and delves a bit into the science behind Optios. He also advises investors and explains how he sees the industry evolving. 

You can visit Optios at www.optios.com.  

David can be contacted via email at david@optios.com.